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We motivate and implement an Artificial Intelligence 
(AI) Computer Aided Diagnosis (CAD) framework, to 
assist clinicians in the early diagnosis of Mild 
Cognitive Impairment (MCI) and Alzheimer’s Disease 
(AD). Our framework is based on a Convolutional 
Neural Network (CNN) trained and tested on 
functional Magnetic Resonance Images datasets. We 
contribute to the literature on AI-CAD frameworks for 
AD by using a 2D CNN for early diagnosis of MCI. 
Contrary to current efforts, we do not attempt to 
provide an AI-CAD framework that will replace 
clinicians, but one that can work in synergy with them. 
Our framework is cheaper and faster as it relies on 
small datasets without the need of high-performance 
computing infrastructures. Our work contributes to 
the literature on digital transformation of healthcare, 
health Information Systems, and NeuroIS, while it 
opens novel avenues for further research on the topic. 
 
1. Introduction  
 
The digital transformation of healthcare has been a 
prominent topic in health information systems (HIS) 
the last decade [1]. Artificial intelligence (AI), as part 
of the digital transformation toolkit, can enable a more 
efficient and effective healthcare provision [2]. One of 
the most promising areas of HIS is the application of 
AI in assisting medical diagnosis via medical images 
[3]. Advances in AI show that such applications can 
perform on par with medical experts on diagnosis via 
Magnetic Resonance Images (MRI) [4], [5], [6]. 
Such applications to date, oppose AI to clinicians’ 
performance [7]. For instance, there have been more 
than 20,000 studies on deep learning (DL) methods for 
MRI analyses the last ten years, which compare the 
performance of AI to clinicians’ performance [8]. 
Recent work suggests that studies should focus on the 
comparison of performance between clinicians using 
AI, and their performance without an AI aid [7]. 
 
The recent global pandemic of COVID-19, 
however, revealed another urgent need of early disease 
diagnosis: the ability to make predictions based on few 
cases. The AI Computer-Aided-Diagnosis (CAD) 
frameworks to date, are based on large amounts of 
data, and require high performance computing (HPC) 
infrastructures. To address that lacuna, we propose a 
synergistic approach, in which clinicians and scientists 
collaborate for faster, cheaper, and more accurate 
diagnosis, while the AI-CAD frameworks can rely on 
small datasets to make accurate-enough predictions. 
Neuro-Information-Systems (NeuroIS), as an 
interdisciplinary field that combines cognitive 
neuroscience and IS, can address this gap and advance 
the theory and practice of HIS [9]. For MRI diagnosis 
with AI, this translates to finding which approaches 
can provide the most efficient diagnosis and apply 
them to assist clinicians with a HIS that compliments 
their knowledge and skills. The literature on AI in 
healthcare to date, focuses on cancer, the nervous 
system, and cardiovascular diseases because these are 
the leading causes of disability and mortality [10]. 
However, a promising frontier where AI can assist 
clinicians is Alzheimer’s Disease (AD). Whilst there 
was limited progress in the search for treatment to 
slow down the progress of AD, last year Biogen 
released promising clinical studies for a new drug. To 
start treatment in early stages, an early diagnosis is 
needed. As it can take up to 20 years before the patient 
shows any cognitive decline, it can be difficult to 
diagnose AD in early stages. An AI-CAD framework 
could assist clinicians in AD diagnosis via MRI. 
In this paper, thus, we motivate and implement an 
AI-CAD framework for the early diagnosis of Mild 
Cognitive Impairment (MCI) and AD to assist 
clinicians. By doing so, we contribute to the extant 
literature on digital transformation of healthcare [1], 
HIS [11], and NeuroIS [12]. The approach that we 
proposed in this paper can be extended for the 
diagnosis of other diseases, and to further enhance the 
digital transformation of healthcare [3]. 







AD is the most common reason for dementia, 
caused by an accumulation of β-amyloid (Aβ) plaques, 
and abnormal amounts of tau proteins in the brain. 
This results in synapse loss, where the impulse does 
not reach the neurons, and in loss of structure or 
function of neurons, including their death, causing 
memory impairment and other cognitive problems 
[13]. More than 44 million people worldwide suffer 
from AD and it is projected to triple by 2050 [14]. AD 
has strong impact on patients’ cognitive and physical 
functioning, resulting in death [15]. Moreover, there is 
also a strong societal and economic impact as global 
cost of AD is estimated at more than $818 billion [14]. 
The recent developments in slowing AD decline 
has increased the relevance of its early diagnosis [16], 
and MCI plays an important role in the early diagnosis 
of AD. MCI is a syndrome where patients have greater 
cognitive decline than expected, but it does not affect 
their lives [18]. Although some MCI patients remain 
stable or return to cognitively normal (CN), there is a 
10-15% risk per year of progression to AD [13]. 
The AD etiology was unknown for the last decade, 
and diagnosis relied on neurocognitive tests [18]. This 
approach was inefficient and unreliable because AD 
could not be distinguished from other dementias. The 
development of biomarkers improved the diagnosis of 
AD, and many studies have focused on identifying 
biomarkers. A common method to diagnose AD is 
hippocampus segmentation, which relates to memory 
function [19], and its small volume is an AD 
biomarker [20]. For a long time, AD diagnosis was 
done manually by looking at the brain structure and 
size of the hippocampus on MRI, which requires a lot 
of practice and precision [21]. There has been an 
increasing amount of studies on automated methods 
for hippocampus segmentation using machine learning 
(ML) and DL with promising results [22], [23]. 
Hippocampus segmentation for the diagnosis of AD 
and MCI, however, requires clinicians’ expertise and 
is sensitive to interrater and intra-rater variability [22]. 
Convolutional Neural Networks (CNN), which is a 
successful method for image classification, can 
support clinicians in diagnosing AD and MCI. CNN 
can significantly improve the performance of image 
classification [24], and are becoming increasingly 
popular in MRI analysis. Recent studies have showed 
that CNN can achieve similar results as a specialist on 
classifying MRI of skin cancer patients [5]. Similar 
approaches with three-dimensional (3D) as well as 
two-dimensional (2D) CNN have also been used for 
AD diagnosis with promising results. The filter of a 
3D CNN slides along the three dimensions of the input 
image, resulting in 3D feature maps, whereas in a 2D 
CNN the filter only slides along the height and width 
of the input image. Therefore, the latter case results in 
2D feature maps with need for less parameters and, 
thus, less computational power and time. Most prior 
studies used 3D CNN, achieving accuracy up to 99% 
for AD diagnosis, and up to 87% for MCI [25], while 
others obtained similar results with 2D CNN [26]. 
A summary of 2D and 3D approaches in the 
literature is shown in Table 1. Prior studies, however, 
have not applied 2D approaches for detecting MCI. 
We will, thus, investigate whether a 2D CNN is 




Neural networks (NN) are inspired by the human 
brain to resolve problems that are simple for humans 
but complex for machines [35]. CNN is the most 
common NN architecture for image analysis. Fully 
connected NN take multiple inputs, and hidden layers 
perform calculations on them, while the neurons 
connect to each other. Neurons in CNN, however, 
connect to others close to them, and all have the same 
weight. CNN thus, need fewer parameters than fully 
connected NN, which results in small risk of 
overfitting, higher accuracy, and faster processing 
time. Moreover, in CNN there is no need to transform 
images to one-dimensional, a process which can result 
in loss of structural information, as CNN learn the 
relationships among pixels of input by extracting 
representative features with kernel convolutions [13]: 
 
Table 1. Performance comparison of 2D and 3D methods 
Study 
2D CNN 3D CNN 
AD MCI AD MCI 
Basaia et al. [25] - - .99 .87 
Feng et al. [27] - - .95 .86 
Korolev et al. [28] - - .80 - 
Liu et al. [29] - - .85 - 
Liu et al. [30] - - .91 - 
Senanayake et al. [31] - - .76 .75 
Hon and Khan [32] .96 - - - 
Sarraf and Tofighi [33] .97 - - - 
Sarraf and Tofighi [34] .99 - - - 
Wang et al. [26] .98 - - - 
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where 𝐼 is the input and 𝐾 is the kernel; the input 
indices are represented by	𝑖 and 𝑗, and the kernel 
indices are represented by 𝑚 and 𝑛. A 2D CNN 
extracts features by sliding along the height and width 
of images, resulting in 2D feature maps. 3D CNN also 
slide along the depth of images thus, the kernel does 
not have the same depth as the input, resulting in 3D 
feature maps. Although previous work established that 
3D CNN perform better for patch classifications, the 
results between 2D and 3D approaches for whole 
image labeling did not differ much [36]. A 3D CNN, 
however, is computationally expensive, and, due to the 
number of parameters, require more training data [37]. 
The data used in the preparation of this article were 
obtained from the Alzheimer’s Disease Neuroimaging 
Initiative (ADNI) database (adni.loni.usc.edu). The 
ADNI was launched in 2003 as a public-private 
partnership. The primary goal of ADNI has been to test 
whether MRI, other biological markers, and clinical as 
well as neuropsychological assessment can be 
combined to measure the progression of MCI and 
early AD. The ADNI is separated into 3 studies of 5 
years, while the first was prolonged by 2 years under 
the name ADNI-GO. In total, 2517 people of ages 55-
90 participated in the study. The ADNI encourages the 
use of their standardized datasets to ensure consistency 
in analysis and direct comparison of various methods 
among studies. We, therefore, used their two 
standardized datasets ‘ADNI1:Complete 2Yr 1.5T’, 
and ‘ADNI1:Complete 3Yr 1.5T’, which contain MRI 
that have passed quality control assessment [38]. 
Our dataset consists of 1941 images, distributed in 
658 MRI of CN subjects, 411 MRI of AD patients, and 
872 MRI of MCI patients. The data come from 99 AD 
patients, 148 MCI patients, and a control group of 135 
CN subjects. We present the demographic information 
of the included subjects in Table 2 to enable 
comparison with the samples used in other studies. 
The dataset was split into one with CN and AD 
subjects (1063 MRI), and one with CN and MCI 
subjects (1524 MRI). Since the participants of the 
ADNI study returned for more than one check-up, any 
patient can have up to 12 MRI, which are not identical 
as they are taken at different moments, and every MRI 
in the standardized dataset was treated independently. 
The standardized datasets are preprocessed, 
without noisy MRI, while three more processing steps 
have been performed: i) gradwarp correction to correct 
inherent nonlinearity of the imaging gradients in MRI 
scanners, ii) B1 non-uniformity for a greater 
acquisition accuracy of the MRI, and iii) bias field 
correction, which can lead to spurious intensity 
variations. Due to the different scanners and 
techniques used by the ADNI, the MRI were of 
different sizes, and, therefore had to be resized. MRI 
with sizes (256, 256, 180), (256, 256, 170), (256, 256, 
166), (256, 256, 184) and (192, 192, 160) were resized 
to be: (192, 192, 160) with the zoom function of the 
Scipy library. In total, 28 MRI from the MCI dataset 
and 11 MRI from the AD dataset had opposite 
dimensions (e.g. 180, 256, 256), which means 
reshaping them would deform them, and, thus, these 
MRI were removed from the dataset. Resizing the 
MRI results in a different range of pixel values, and, 
therefore, to assure that the pixel values of all MRI had 
the same range, min-max normalization was applied, 






where 𝑥 is the MRI data and 𝑧! the 𝑖th normalized MRI. 
The dataset was then split into train set, validation set, 
and test set with ratio 60:20:20. After preprocessing, 
our AD dataset consisted of 1063 MRI, with 652 CN, 
and 411 AD, while the MCI dataset consisted of 1524 
MRI, with 872 MCI, and 652 CN subjects. 
 
Table 2. Demographic information 
 MCI AD CN 
Images 891 412 662 
Subjects 148 99 135 
Gender 105 M / 43 F 52 M / 47 F 66 M / 69 F 
Age 
μ = 75.59 
σ = 7.40 
μ = 75.85 
σ = 7.61 
μ = 77.19 
σ = 5.24 
 
 
Figure 1. Convolutional network architecture 
 
 
Table 3. Convolutional network architecture 
Layer C1 P1 C2 P2 FC1 FC2 FC3 
Kernel 3x3 2x2 3x3 2x2 - - - 




A NN consists of an input layer, hidden layers, and 
an output layer. A CNN has hidden layers divided into 
convolution, pooling, activation, and classification 
layers. We based our architecture on LeNet-5, which 
includes two convolutional layers, two pooling layers, 
and two fully connected layers (Figure1 and Table 3). 
The Rectified Linear Unit (ReLU) is the most 
commonly used activation function in DL because of 
its simplicity and performance [39], [40], but when the 
activation values are zero, the gradient will be zero 
from that point on and, thus, the model will not learn 
anymore. This is also referred to as the dying ReLU 
problem. As a remedy, we employ the Leaky Rectified 
Linear Unit (LReLU) as activation function for all 
convolutional layers. LReLU addresses this problem 
by allowing for a small non-zero gradient [41]. The 
LReLU activation function in our model is defined as: 
 
𝑦(𝑥) = 4 𝑥, 𝑖𝑓𝑥 < 00.01𝑥, 𝑜𝑡ℎ𝑒𝑟𝑤𝑖𝑠𝑒 
 
where 𝑥 is the input. A Sigmoid activation function 
was applied to the dense layer, which outputs the 
probability of the images’ class, with 0 if healthy and 
1 if sick (AD or MCI). The Sigmoid function in our 




(1 + 𝑒$%) 
 
The batch size was set to 32, and the optimizer of the 
model was Adam [42], with a learning rate of 10-4. 
The CNN was built in a Jupyter Notebook using 
Python 3.6.4, Tensorflow 2.1.0, and Keras 2.3.1. 
TensorFlow is an interface for expressing ML 
algorithms, and an implementation for executing them 
[43]. Keras is a NN application programming interface 
(API), designed to enable fast experimentation with 
NN [44]. To load the MRI in NIfTI format, the Nilearn 
library was used, which is developed especially for 
statistical learning on NeuroImaging data. The scikit-
learn and SciPy libraries were used for data 
preprocessing. The development, testing, and 
application of the model took place on Google Cloud 
Console, where we used a storage bucket to store the 
datasets, and one compute engine instance with 64 




The model evaluation was measured in accuracy, 
recall, precision, and f1-score. Recall provides 
sensitivity information on how many patients were 
correctly identified. Precision expresses how many of 
the positives that the model returns were actually 
positive. F1-score is the harmonic mean between 
precision and recall. A NN adjusts its weights to 
optimize the loss, which is calculated with the use of 
binary cross entropy loss: 
 





where 𝐶 represents the classes, 𝑠! is the predicted 
probability value for class 𝑖, and 𝑡 is the true 
probability for that class. Since the data was unevenly 
distributed, the accuracy baseline of random guessing 
was also calculated. The baseline was calculated with 
respect to the class distribution of the dataset. First, we 
trained and tested our model on the AD dataset. After 
passing the baseline of random guessing on the 
training data (>.725) with an accuracy of .910, we 
applied the same model on the MCI dataset. The 
random guessing baseline for the test dataset of the AD 
model was .519 and for the test dataset of the MCI 
model was .507. Models’ over-epochs performance is 
shown in figure 2 for AD, and in figure 3 for MCI. 
The graphs indicate a normal learning curve, 
however, as the performance keeps increasing on the 
train data, the validation performance flattens, which 
implies overfitting. This appears to be stronger on the 
MCI dataset than on the AD dataset. Our model 
achieved an accuracy of .732 on the AD test-set. 
Irrespective of overfitting, the achieved test accuracy 





Figure 2. Model performance on AD dataset. 




Figure 3. Model performance on MCI dataset. 
Left: Accuracy; Right: Loss 
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The model predicted MCI with accuracy of .734, 
passing the random guessing baseline of .507, and 
appeared to be overfitting. Table  4 presents the 
performance metrics of the models on the test sets. 
 
The model performs better than chance on both 
datasets, with similar loss, accuracy, and precision, 
and achieves a better recall on the MCI data as 92.3% 
of the MCI patients were correctly identified. The MCI 
dataset was larger than the AD one, which may explain 
why the performance of MCI is similar to predicting 




Comparing our study to previous ones, we find a 
large difference in dataset size (Table 5). Some of the 
prior studies only report the number of subjects, but 
the number of images can differ from these since one 
subject can have up to 12 images in these datasets. As 
expected, studies with larger datasets, achieved a 
higher accuracy. Moreover, some studies with a 2D 
method treated the slices independently, thereby 
enlarging the size of their dataset, however, the MRI 
is not treated as a whole. We are able, thus, to predict 
AD better than chance by .213, and MCI by .227. 
We expected the model to perform worse on 
detecting MCI than AD, which was not the case. 
Although the results for predicting MCI are better than 
the AD ones, we cannot conclude that the model 
performs better for MCI than for AD, as the MCI 
dataset was larger than the AD one. The MCI dataset 
had 489 more positive labels than the AD dataset. Our 
work, thus, resulted in an AI-CAD framework that can 
assist clinicians in the early diagnosis of MCI and AD 
with high-enough accuracy, based on a small dataset, 




The implications of our work are threefold. First, 
we contribute to the line of research on using CNN for 
AD and MCI diagnosis, by applying a 2D approach. 
Table 5. Comparison of data and accuracy with previous studies 
Study Subjects Images Dimensions 
Accuracy 
AD MCI 
Basaia et al. [25] 645 - 3D .99 .87 
Feng et al. [27] 193 - 3D .95 .86 
Korolev et al. [28] 111 111 3D .80 - 
Liu et al. [29] 193 - 3D .85 - 
Liu et al. [30] 902 - 3D .91 - 
Senanayake et al. [31] - 322 3D .76 .75 
Hon and Khan [32] * 200 6400 2D .96 - 
Sarraf and Tofighi [33] ** 43 367,200 2D .97 - 
Sarraf and Tofighi [34] ** 302 62,335 2D .99 - 
Wang et al. [26] ** 98 17,738 2D .98 - 
Our 234 1,063 2D .73 .73 
*  accuracy before transfer learning = .74 
**  used fMRI slices independently 
 
Table 4. Performance metrics on test data 
Data Loss Acc. Prec. Recall F1 MRI 
AD 1.261 .732 .876 .640 .740 1074 
MCI 1.101 .734 .822 .923 .870 1553 
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Second, whilst AI-CAD frameworks have been 
thoroughly studied, they have not been proposed as a 
tool for assisting clinicians. Moreover, the existing 
approaches are often complicated, and make use of 
large amounts of data. Our proposed framework 
provides high-enough accuracy to assist clinicians in 
their diagnosis for early AD and MCI without the need 
of large datasets or HPC infrastructures. Our proposed 
approach can also be extended for other diseases, as 
well as for cases where time is scarce or limited data 
is available. Furthermore, whilst the literature on AI-
CAD frameworks is mostly approached from a 
computer science perspective, clinicians have been 
shown to lack trust in them [46]. Our work addresses 
that lacuna by providing a synergistic approach 
between clinicians and scientists, thereby contributing 
to the literature on HIS [11] and NeuroIS [12]. The 
NeuroIS literature focusses on different disciplines 
from theory-focused to design-focused [9]. Our final 
contribution, thus, is on bridging these disciplines. The 
work we present here, thus, extends current efforts in 




Our approach has some limitations that should be 
acknowledged. First, some preprocessing steps were 
not performed because of the required operating 
system (OS). An important step in MRI preprocessing 
is skull stripping. In this step, the brain tissue is 
removed from the image to reduce noise. Commonly 
used techniques are the brain extraction tool (BET) 
[45], the Brain Surface Extractor (BSE) [47], and the 
Robust Brain Extraction (ROBEX) [48]. The 
automated methods in Python for these techniques, 
however, are only useable under Unix. Due to the used 
OS, skull stripping could not be applied to all images 
in the dataset and was therefore omitted. As noise in 
the data can lead to unexpected results in classification 
due to false feature extraction, it is expected that 
skipping this step has direct consequences to the 
performance of the CNN. Skull stripping (BET2 in 
particular) leads to a better segmentation [49], it is 
however difficult to say how large the impact is for 
classification tasks. Second, our model showed 
overfitting, which means that it includes more terms or 
uses more complicated approaches than necessary 
[50]. Regularization can control overfitting and drop-
out regularization is a commonly used approach 
because it is computationally inexpensive, and it 
prevents co-adaptation among feature map units [37]. 
We added dropout regularization to our model, and 
although it performed slightly better on training and 
validation data, it performed worse on the test data. 
For that reason, we omitted dropout regularization.  
5.3. Future Research 
 
Our work offers a faster and cheaper method for 
classifying MRI, as resources can be saved from not 
having to acquire computational power. We proposed 
a 2D approach for MCI and AD detection because the 
3D one has drawbacks related to its computational 
requirements. As a next step of our research project, 
we intend to replicate the existing 3D approaches in 
the literature, and compare their execution time with 
the one of our model’s, on the same computational 
infrastructure. Such a comparison of execution time 
will further illustrate the merits of our proposed 
approach before proposing it for testing and 
implementation to the broader healthcare system. 
Whilst we will further develop the accuracy of the 
model before proceeding, our next step is to evaluate 
the performance of clinicians using our AI-CAD 
framework, and their performance without the AI aid. 
For this step, we have already established 
collaboration with hospitals and clinics that have 
geriatric units specializing in AD and MCI, and we are 
ready to proceed with a pilot phase. Such collaboration 
will provide us with unique datasets to further enhance 
the externality of our model, as most studies using 
CNN on AD and MCI are based on the ADNI datasets. 
Moreover, quantum computing (QC) is a new 
paradigm that could offer a solution to the challenge 
we address. The field of quantum DL provides 
innovative algorithms that offer significant speedups 
over the classical DL approaches [51]. We aim, thus, 
to further develop an AI-CAD framework with a 
Quantum CNN (QCNN). In classical computing a bit 
can either be |0⟩ or |1⟩; a qubit in QC can be |0⟩, |1⟩, 
or in a superposition state 𝛼|0⟩ + 𝛽|1⟩ with 
amplitudes (𝛼, 𝛽) 	∈ 	𝐶 such that |𝛼| " +  |𝛽| " = 1. In 
classical computing, processes are executed in 
sequence, while in QC processes run simultaneously 
further optimizing, thus, the total run time. Moreover, 
QCNN do not suffer from the issue of causal 
asymmetry that can affects classic CNN [52]. Should 
the QC paradigm become more easily accessible in the 
coming years, such an approach can provide clinicians 
with fast access to predictive models to address urgent 
situations, as well as the lack of large datasets. 
 
6. Conclusion  
 
Prior studies have used CNN to diagnose MCI and 
AD, most of which applied 3D approached, with 
promising results. 3D CNN, however, has drawbacks 
that relate to needs for HPC infrastructures. Other 
studies have focused on detecting AD with a 2D CNN, 
achieving similar results as the 3D approach. Despite 
Page 3412
the relevance of detecting MCI, prior studies did not 
investigate how these methods perform on detecting 
MCI. Our main goal was to determine whether a 2D 
CNN can be used to diagnose AD and MCI. Our work 
resulted in an AI-CAD framework that can assist 
clinicians in the early diagnosis of MCI and AD with 
high-enough accuracy, based on a small dataset, and 
without the need of HPC infrastructures. Our next step 
will be to evaluate the performance of clinicians with 
and without the use of our AI-CAD framework. As a 
follow-up study, we intent to develop an AI-CAD 
framework with a QCNN, which could provide 
clinicians with fast access to predictive models to 
address urgent situations and the lack of large datasets. 
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